Effect of Ketamine in the Treatment of Patients with Major Depressive Disorder

BACKGROUND AND OBJECTIVE: Major depressive disorder is a common and destructive mental disorder with relatively long episodes, high tendency to be chronic and recurrence, and responsible for many physical and mental disabilities that has the lifetime prevalence of about 17% to 19%. With regard to th...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	F Kheirkhah, AA Moghadamnia, G Tayebi, A Bijani, P Tayebi, A Salavati
Formato:	article
Lenguaje:	EN FA
Publicado:	Babol University of Medical Sciences 2010
Materias:	major depressive disorders mood disorders ketamine nmda receptor antagonist Medicine R Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/05f8e59e778e464abfbea5ee17cbe947
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:05f8e59e778e464abfbea5ee17cbe947
record_format	dspace
spelling	oai:doaj.org-article:05f8e59e778e464abfbea5ee17cbe9472021-11-10T09:00:36ZEffect of Ketamine in the Treatment of Patients with Major Depressive Disorder1561-41072251-7170https://doaj.org/article/05f8e59e778e464abfbea5ee17cbe9472010-10-01T00:00:00Zhttp://jbums.org/article-1-3662-en.htmlhttps://doaj.org/toc/1561-4107https://doaj.org/toc/2251-7170BACKGROUND AND OBJECTIVE: Major depressive disorder is a common and destructive mental disorder with relatively long episodes, high tendency to be chronic and recurrence, and responsible for many physical and mental disabilities that has the lifetime prevalence of about 17% to 19%. With regard to the improvement of non responder patients to routine treatment following a single dose injection of ketamine, this study was done to investigate the effect of ketamine on patients with major depressive disorder (MDD). METHODS: This clinical trial study (semi-experimental design) was performed on 60 patients with MDD according to DSM IV-TR criteria. A single intravenous dose of ketamine (0.5 mg/kg) was given to the patients. Depression level of all patients was assessed before injection, on the days 2 and 7 after injection of ketamine and at the end of 1st and 2nd months based on Beck and Hamilton Depression Scale. Criteria for response to treatment with ketamine was reduction of 50% or greater in Hamilton and Beck scores. FINDINGS: The results showed that mean score for Hamilton test before injection, on the days 2 and 7 after injection was 28.71±9.12, 20.57±10.88 and 16.85±10.70, respectively and mean score for Beck test before injection, on the days 2 and 7 after injection was 32.28±13.96, 25.05±14.10 and 19.71±13.40, respectively that significantly decreased as compared to before injection (p<0.05). The results of the scores decreased over 50% in about 20% of patients on the second day and 40% on the seventh day after injection of ketamine. Improving symptoms of depression in these patients was not associated with other variables such as age, sex, marital status, residence place, education level and season of injection. CONCLUSION: With regard to easy administration, rapid effect and appropriate duration of action of intravenous single dose of ketamine in patients with MDD, it can be a good alternative for acute phase treatment of major depression.F KheirkhahAA MoghadamniaG TayebiA BijaniP TayebiA SalavatiBabol University of Medical Sciencesarticlemajor depressive disordersmood disordersketaminenmda receptor antagonistMedicineRMedicine (General)R5-920ENFAMajallah-i Dānishgāh-i ̒Ulūm-i Pizishkī-i Bābul, Vol 12, Iss 4, Pp 14-20 (2010)
institution	DOAJ
collection	DOAJ
language	EN FA
topic	major depressive disorders mood disorders ketamine nmda receptor antagonist Medicine R Medicine (General) R5-920
spellingShingle	major depressive disorders mood disorders ketamine nmda receptor antagonist Medicine R Medicine (General) R5-920 F Kheirkhah AA Moghadamnia G Tayebi A Bijani P Tayebi A Salavati Effect of Ketamine in the Treatment of Patients with Major Depressive Disorder
description	BACKGROUND AND OBJECTIVE: Major depressive disorder is a common and destructive mental disorder with relatively long episodes, high tendency to be chronic and recurrence, and responsible for many physical and mental disabilities that has the lifetime prevalence of about 17% to 19%. With regard to the improvement of non responder patients to routine treatment following a single dose injection of ketamine, this study was done to investigate the effect of ketamine on patients with major depressive disorder (MDD). METHODS: This clinical trial study (semi-experimental design) was performed on 60 patients with MDD according to DSM IV-TR criteria. A single intravenous dose of ketamine (0.5 mg/kg) was given to the patients. Depression level of all patients was assessed before injection, on the days 2 and 7 after injection of ketamine and at the end of 1st and 2nd months based on Beck and Hamilton Depression Scale. Criteria for response to treatment with ketamine was reduction of 50% or greater in Hamilton and Beck scores. FINDINGS: The results showed that mean score for Hamilton test before injection, on the days 2 and 7 after injection was 28.71±9.12, 20.57±10.88 and 16.85±10.70, respectively and mean score for Beck test before injection, on the days 2 and 7 after injection was 32.28±13.96, 25.05±14.10 and 19.71±13.40, respectively that significantly decreased as compared to before injection (p<0.05). The results of the scores decreased over 50% in about 20% of patients on the second day and 40% on the seventh day after injection of ketamine. Improving symptoms of depression in these patients was not associated with other variables such as age, sex, marital status, residence place, education level and season of injection. CONCLUSION: With regard to easy administration, rapid effect and appropriate duration of action of intravenous single dose of ketamine in patients with MDD, it can be a good alternative for acute phase treatment of major depression.
format	article
author	F Kheirkhah AA Moghadamnia G Tayebi A Bijani P Tayebi A Salavati
author_facet	F Kheirkhah AA Moghadamnia G Tayebi A Bijani P Tayebi A Salavati
author_sort	F Kheirkhah
title	Effect of Ketamine in the Treatment of Patients with Major Depressive Disorder
title_short	Effect of Ketamine in the Treatment of Patients with Major Depressive Disorder
title_full	Effect of Ketamine in the Treatment of Patients with Major Depressive Disorder
title_fullStr	Effect of Ketamine in the Treatment of Patients with Major Depressive Disorder
title_full_unstemmed	Effect of Ketamine in the Treatment of Patients with Major Depressive Disorder
title_sort	effect of ketamine in the treatment of patients with major depressive disorder
publisher	Babol University of Medical Sciences
publishDate	2010
url	https://doaj.org/article/05f8e59e778e464abfbea5ee17cbe947
work_keys_str_mv	AT fkheirkhah effectofketamineinthetreatmentofpatientswithmajordepressivedisorder AT aamoghadamnia effectofketamineinthetreatmentofpatientswithmajordepressivedisorder AT gtayebi effectofketamineinthetreatmentofpatientswithmajordepressivedisorder AT abijani effectofketamineinthetreatmentofpatientswithmajordepressivedisorder AT ptayebi effectofketamineinthetreatmentofpatientswithmajordepressivedisorder AT asalavati effectofketamineinthetreatmentofpatientswithmajordepressivedisorder
_version_	1718440252895395840

Effect of Ketamine in the Treatment of Patients with Major Depressive Disorder

Ejemplares similares